News
LL-37: Immunity, Microbial Defense, and Regenerative Research
LL-37, a 37-amino acid peptide derived from the cathelicidin antimicrobial peptide precursor hCAP18, has emerged as a molecule of considerable research interest. Encoded by the CAMP gene, LL-37 is the only known cathelicidin and is expressed in a variety...
Business & Industry
Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal
LaNova Medicines, which happens to be a cancer drugmaker that previously licensed medicines to AstraZeneca as well as Merck & Co., has gone on to agree to get acquired by Sino BioPharmaceuticals in a deal worth almost $951 million.
In...
News
Rheumatoid Arthritis Treatment with Genetic Link Adds Hope
Researchers at the University of Edinburgh have gone on to identify a genetic link that could revolutionize rheumatoid arthritis treatment. This discovery now opens the doors to innovative drug development as well as better patient outcomes, potentially elevating the...
News
Sleep Lean Reviews – Is It Effective for Weight Loss?
Sleep Lean is a dietary supplement formulated for people who want to enhance deep sleep and support healthy weight loss. Designed as a dual-action formula, Sleep Lean helps user’s burn fat and rest well by targeting both stress levels...
Clinical Trials
CDSCO Moves to Online Submission for CGTP Trial Applications
As part of its continued efforts to streamline operations through digitisation, the Central Drugs Standard Control Organisation (CDSCO) has transitioned from offline to online acceptance of clinical trial applications for cell and gene therapies products (CGTP).
The agency has also...
News
Singapore Seeking Pharmaceutical Tariff Concessions from US
The deputy prime minister and trade minister of Singapore, Gan Kim Yong, has announced his plans to visit Washington this July in order to negotiate certain pharmaceutical tariff concessions on exports, thereby looking forward to shielding one of the most...
News
Merck to Acquire Verona for $10B, COPD Drug in Focus
Merck has pulled off another acquisition that happens to fit in its sweet spot, says Rob Davis, its CEO. As Merck acquires Verona Pharma after paying $10 and with it gets its potential blockbuster drug Ohtuvayre, a first-in-class treatment...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read